Sumitomo Chemical India · risk themes across the available quarters.
Bear-case history
While Rabi conditions appear favorable, any disruption from unseasonal rains or adverse weather could further impact H2 recovery, which is critical for annual growth targets. This risk was raised by multiple analysts.
Entire bio-stimulants industry faced sales halt from mid-June to end-September due to new regulations requiring license endorsement at manufacturing sites and state level. Varad BioSciences' 9% revenue contribution (down from 11%) remains at risk until full regulatory clearances are obtained.
Despite being discussed for years, Dahej project timelines continue to extend. Management now indicates 2028 for initial revenues, raising questions about execution capability and parent company coordination efficiency.
Brazil sales declined 33% YoY due to channel inventory liquidation and shipment delays, with no firm timeline for recovery. Analyst raised concern about international business growth expectations not materializing as planned.
IMD forecasts southwest monsoon at 92% of long-period average (below normal), with 82% probability of El Niño emergence during May-July. This could significantly impact rabi season recovery and full-year demand.
Depreciating rupee, escalating costs across raw materials, packaging materials, solvents, and transportation driven by geopolitical developments. Management has implemented three price increases but sustainability of pass-through remains uncertain.
Global container availability constrained towards end of Q4 and into early FY27, with shipment delays experienced including to Africa. Management characterizes this as episodic and manageable rather than structural.
Net working capital days increased to 103 from 89 days year-over-year due to deliberate inventory buildup ahead of kharif. This represents tied-up capital in a rising cost environment.